Narcolepsy Therapeutics Market is expected to reach US$ 6.98 billion by 2033 | Top key players - Novartis AG, Avadel, Apotex Inc.

Market Size and Growth:

The Global Narcolepsy Therapeutics Market size reached US$ 2.93 billion in 2023, with a rise to US$ 3.19 billion in 2024, and is expected to reach US$ 6.98 billion by 2033, growing at a CAGR of 9.1% during the forecast period 2025-2033. The Market is driven by rising disease awareness, improved diagnostic rates, and the introduction of novel, more effective treatment options. According to DataM Intelligence

To Download a Free Sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/narcolepsy-therapeutics-market?sz

The Narcolepsy Therapeutics Market refers to the global industry focused on developing, manufacturing, and marketing drugs and therapies to treat narcolepsy a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations. This market includes pharmaceutical treatments, emerging biologics, and novel drug delivery systems aimed at improving patient outcomes and sleep regulation.

Industry Recent Developments: United States

✅ October 2025: The U.S. Narcolepsy Therapeutics Market continues to grow rapidly driven by rising disease awareness, improved diagnostics, and innovative drug developments, including orexin receptor agonists and extended-release formulations approved by the FDA. Key players like Jazz Pharmaceuticals and Harmony Biosciences lead innovation with sodium oxybate and pitolisant treatments. Clinical trial enrollment has improved along with public awareness, leading to better treatment compliance and efficacy.

✅ August 2025: The U.S. narcolepsy drugs market is projected to grow significantly, expected to reach about $2.23 billion by 2033, with steady expansion attributed to increasing prevalence of sleep disorders, ongoing drug development, and supportive regulatory environment. The FDA keeps approving novel formulations improving symptom management and patient adherence.

✅ July 2025: Takeda announced overwhelmingly positive results from two Phase III trials (FirstLight and RadiantLight) for overporexton, an orexin receptor agonist drug, showing significant improvements in narcolepsy type 1 symptoms, marking a milestone in mechanism-based therapies for narcolepsy.

Industry Recent Developments: Japan

✅ October 2025: The Japan narcolepsy therapeutics market is valued in the mid-hundreds of millions USD, expected to grow at around 8% CAGR through 2030. Key market players in Japan include Teva Pharmaceutical, Jazz Pharmaceuticals, Harmony Biosciences, Novartis, Shionogi, and Takeda. Narcolepsy with cataplexy is the largest revenue segment in Japan.

✅ September 2025: Takeda is advancing a new class of therapies aimed at orexin receptor 2, targeting the biological root cause of narcolepsy. Late-stage clinical data show significant clinical improvements for narcolepsy patients, positioning this as the first therapy addressing narcolepsy's root mechanism.

✅ October 2025: Aculys Pharma in Japan received marketing approval for Spydia Nasal Spray drug formulations, expanding treatment options in the narcolepsy and related neurological disorder therapeutics market.

Get Customization in the report as per your requirements + Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/narcolepsy-therapeutics-market?sz

FDA Approvals:

✅ Amneal - FDA approval (final) of a sodium oxybate oral solution (ANDA) - Sept 11, 2025. Amneal's 500 mg/mL sodium-oxybate oral solution (ANDA referencing Xyrem) received U.S. FDA approval, adding another entrant in the oxybate category and increasing generic/affordable options for cataplexy and EDS.

✅ Pitolisant (WAKIX) - Generic ANDA: Tentative approval for Pitolisant tablets (Biophore/Zenara) - ANDA tentative approval letter issued Feb 18, 2025. The FDA found the ANDA bioequivalent but could not grant final approval because of listed patents/exclusivity on the reference product (WAKIX). This is a major step toward a generic pitolisant but final approval is blocked until patent/exclusivity issues are resolved. (See the FDA ANDA tentative approval letter.)

Regulatory Decisions / Regulatory setbacks in 2025:

✅ Harmony Biosciences - FDA Refusal-to-File (RTF) for pitolisant sNDA (idiopathic hypersomnia indication) - Feb 19, 2025 (company announcement / press coverage). The FDA issued an RTF for Harmony's supplemental NDA seeking an idiopathic hypersomnia (IH) indication for pitolisant, citing shortcomings related to the submission (the Phase 3 INTUNE study did not meet its primary endpoint). Harmony stated it will pursue a registrational Phase 3 for a high-dose formulation. This is a meaningful regulatory setback for label expansion efforts in 2025.

✅ Avadel / LUMRYZ - FDA regulatory activity for IH (Orphan Drug Designation) - June 5, 2025 (regulatory designation). The FDA granted Orphan Drug Designation to Avadel's LUMRYZ for idiopathic hypersomnia (IH) - a regulatory designation (not full approval) that can confer exclusivity and development incentives while Avadel runs registrational studies for IH.

Mergers & Acquisitions (2025):

✅ Alkermes announces agreement to acquire Avadel Pharmaceuticals (deal announced Oct 22, 2025) - Oct 22, 2025. Alkermes agreed to buy Avadel (maker of LUMRYZ) in a deal valued up to about $2.1 billion (cash + contingent value right tied to potential IH approval of Lumryz). The transaction is positioned as Alkermes' entry into the sleep-medicine/narcolepsy space and centers on Lumryz's commercial footprint. (Transaction expected to close Q1 2026, per announcements.)

Major Key Players:

Jazz Pharmaceuticals, Inc.
Avadel
Apotex Inc.
Novartis AG
Harmony Biosciences.

Segments Covered in the Narcolepsy Therapeutics Market:

By Disease Type: Narcolepsy Type 1, Narcolepsy Type 2.

By Therapeutic Type: Central Nervous System Stimulants, Central Nervous System Depressants, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies.

Regional Analysis for Narcolepsy Therapeutics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=narcolepsy-therapeutics-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Narcolepsy Therapeutics market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Narcolepsy Therapeutics Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Narcolepsy Therapeutics market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Narcolepsy Therapeutics Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Narcolepsy Therapeutics market?

➠ Who are the global key manufacturers of the Narcolepsy Therapeutics Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Narcolepsy Therapeutics market opportunities and threats faced by the vendors in the global Narcolepsy Therapeutics Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Narcolepsy Therapeutics market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.